GSK India's Q2FY26 Performance: EBIDTA Margin Grows By 250 Basis Points, Oncology Portfolio Off to a Strong Start

GlaxoSmithKline Pharmaceuticals Ltd (GSK India) announced its financial results for the second quarter ended September 30, 2025. Despite muted topline growth due to temporary challenges, the Company demonstrated strong profitability with sustained leadership in anti-infectives, dermatology and vaccines. The General Medicines portfolio delivered competitive performance, with key promoted brands achieving market share gains. The Vaccines business saw market share expansion, and the Adult vaccines business continues to see strong traction. GSK’s entry into Oncology with the launch of its specialised therapies Jemperli (Dostarlimab) and Zejula (Niraparib) have been well-received by Healthcare Professionals.